INO - Inovio Pharmaceuticals Inc Stock Price, Fair Value and News

11.32USD+0.37 (+3.38%)Market Closed

Market Summary

USD11.32+0.37

Market Closed

3.38%

INO Stock Price

View Fullscreen

INO RSI Chart

INO Valuation

Market Cap

293.3M

Price/Earnings (Trailing)

-2.35

Price/Sales (Trailing)

70.51

EV/EBITDA

-2.03

Price/Free Cashflow

-2.52

INO Price/Sales (Trailing)

INO Profitability

EBT Margin

-3248.31%

Return on Equity

-132.29%

Return on Assets

-96.77%

Free Cashflow Yield

-39.73%

INO Fundamentals

INO Revenue

Revenue (TTM)

4.2M

Rev. Growth (Yr)

-32.03%

Rev. Growth (Qtr)

1.4K%

INO Earnings

Earnings (TTM)

-124.9M

Earnings Growth (Yr)

25.04%

Earnings Growth (Qtr)

-21.86%

Breaking Down INO Revenue

Last 7 days

5.5%

Last 30 days

42.4%

Last 90 days

3.6%

Trailing 12 Months

75.5%

How does INO drawdown profile look like?

INO Financial Health

Current Ratio

4.77

INO Investor Care

Shares Dilution (1Y)

18.34%

Diluted EPS (TTM)

-5.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	4.2M	0	0	0
2023	12.3M	13.7M	4.9M	4.9M
2022	2.7M	2.7M	11.5M	10.8M
2021	8.3M	8.2M	7.6M	2.8M
2020	2.6M	3.5M	3.6M	8.9M
2019	31.8M	7.5M	6.3M	4.1M
2018	39.3M	36.4M	33.4M	30.5M
2017	37.6M	51.8M	41.9M	42.2M
2016	43.5M	44.4M	32.8M	35.4M
2015	13.3M	14.8M	37.1M	40.6M
2014	14.4M	17.4M	9.7M	10.5M
2013	3.9M	4.2M	12.9M	13.5M
2012	8.4M	6.4M	4.6M	4.1M
2011	7.9M	9.2M	10.5M	9.8M
2010	0	8.1M	7.1M	6.1M
2009	0	0	0	9.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

CEO	Dr. Jacqueline E. Shea Ph.D.
WEBSITE	inovio.com
INDUSTRY	Biotechnology
EMPLOYEES	135

Inovio Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Inovio Pharmaceuticals Inc? What does INO stand for in stocks?

INO is the stock ticker symbol of Inovio Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inovio Pharmaceuticals Inc (INO)?

As of Thu Jul 25 2024, market cap of Inovio Pharmaceuticals Inc is 283.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INO stock?

You can check INO's fair value in chart for subscribers.

Is Inovio Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether INO is over valued or under valued. Whether Inovio Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Inovio Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INO.

What is Inovio Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, INO's PE ratio (Price to Earnings) is -2.27 and Price to Sales (PS) ratio is 68.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Inovio Pharmaceuticals Inc's stock?

In the past 10 years, Inovio Pharmaceuticals Inc has provided -0.226 (multiply by 100 for percentage) rate of return.